Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics. BMS is best known as an early pioneer of ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results